| Project/Area Number |
25860989
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
KANAHARA Nobuhisa 千葉大学, 社会精神保健教育研究センター, 講師 (70507350)
|
|---|
| Research Collaborator |
ODA Yasunori
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 治療抵抗性統合失調症 / ドパミン過感受性精神病 / 遅発性ジスキネジア / 抗精神病薬 / GRK6 / βアレスチン2 |
|---|
| Outline of Final Research Achievements |
1）In our epidemiological survey, dopamine supersensitivity psychosis is observed with higher incident ratio in treatment-resistant patients than in general patients. 2) Getetic association study to examine the possible effects of GRK6 and ARRB2 which are involved in dopamine D2 receptor metabolism, revealed no significant distributioin in a total of 8 single nucleotide polymorphism of both molecules between patients with and without dopamine supersensitivity psychosis. 3) In the animal model of dopamine supersensitivity psychosis, the rat group with haloperidol administration showed lower ARRB2 in the striatum compared to the control group (saline administration). These results suggested that dopamine supersensitivity state is possibly involved in refractoriness in schizophrenia, regardless of continous pharamacotherapy.
|
